Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH

Executive Summary

Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.

Advertisement

Related Content

Abbott Becomes CRM Player Overnight By Completing St. Jude Deal
Abbott Steps Up Effort To Abandon Alere Deal
Boston Scientific Stops Roll-Out Of Lotus Edge TAVR To Resolve Locking Problem
Boston Scientific Buys EndoChoice, Mulls De-FUSEing Potential Weakness
US FDA Approves First Intermediate-Risk Indication For TAVR
Earnings Winners And Losers: BSX, CYNO, EW, GB, STJ, BCR, EXAC
Expanded Indication For Edwards’ Sapien 3 Squarely In Sight
Neuromodulation 2016: Competition Heats Up In Spinal Cord Stim Market
TCT 2015 ROUND UP: More Transcatheter Aortic Valve Results, Super-Thin Strut Stents, and Percutaneous Heart Pumps
Boston Sci’s Watchman Stroke Device Finally Lands FDA Approval, With Favorable Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT104392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel